P
PTM Biolabs
High throughput proteomics technology and premium epigenetics reagents
About PTM Biolabs
PTM Biolabs is a biotechnology startup that operates in the field of epigenetics and proteomics, which are areas of study that focus on understanding how genes function and proteins interact within the human body. The company offers a range of services, including drug research and development, in-depth blood proteomics, and pan PTM antibodies. These services are primarily targeted towards the healthcare and pharmaceutical industries, where they can be used to better understand complex human health and disease states.
The company's business model revolves around providing these specialized services to its clients. They generate revenue by charging for these services, which are likely to be in high demand given the increasing interest in personalized medicine and the growing need for more effective drugs and treatments.
PTM Biolabs also appears to be actively involved in industry events, such as the MEDICA and AACC Annual Meeting and Clinical Lab Expo. This suggests that the company is not only focused on its research but also on staying connected with the broader scientific community and keeping up-to-date with the latest developments in its field.
In terms of market, PTM Biolabs operates in the rapidly growing biotechnology industry. This industry is driven by advancements in technology and an increasing understanding of human biology, which are enabling new and innovative approaches to healthcare and medicine.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2020 | $80M | $320M | IDG Capital · Highlight Capital · SDIC Venture Capital · Fortune Capital | — |
| SPINOUTOther financing | Jan 2011 | $0 | — | The University of Chicago | — |
Growth signals
Latest recorded traffic for PTM Biolabs is 160 monthly website visits, down 79.5% over the last three months. PTM Biolabs's team declined 9.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
IDG Capital
Highlight Capital
SDIC Venture Capital- FCFortune Capital
Other known investors1 additional known investor
The University of Chicago
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PTM Biolabs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PTM Biolabs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







